FEB
03

MISTIE Treatment Success at University of Kansas

Dr. Paul Camarata, a neurosurgeon and investigator for the MISTIE trial, was interviewed today about the successful treatment of a patient at the University of Kansas Medical CenterMIS stands for minimally-invasive surgery and is the technique used to place a catheter into the patient's intracerebral hematoma. (ICH, also called intracerebral hemorrhage, is a type of stroke caused by bleeding in the brain). A drug called tissue plasminogen activator (tPA) is then administered into this catheter for 1 to 3 days to breakup the blood clot (by enhancing a natural process called thrombolysis) so it can be drained out of the catheter.

Continue reading
JAN
22

200th Patient Enrolled in CLEAR-III

BIOS (Johns Hopkins' Brain Injury Outcomes clinical trial coordinating center) is thrilled to announce the CLEAR III consortium reached an important milestone today: enrollment in the CLEAR III trial has reached 200 patients! That means we are now 40% of the way to our goal of enrolling 500 patients by the end of 2014. At this rate, we are on target to complete enrollment six months or more ahead of schedule, something that will be a major accomplishment for this international study! What a great team of investigators and coordinators we have!!!

Congratulations to Dr. Agnieszka Ardelt (principal investigator), Cedric McKoy (coordinator), and the rest of the team at University of Chicago for enrolling patient #4200 today. As the treatment is blinded, we don't know whether this patient received tPA or the placebo, but after only 3 doses both the IIIrd and IVth ventricles are now open and his Modified Graeb score has dropped from 15 to 7, definitely an improved prognosis for this still critically-ill patient after experiencing a 30cc intracerebral hematoma that expanded into a large intraventricular hemorrhage.

We update the patient-by-patient enrollment information each week. Also, you can read the Quarterly Assessment of Performance (QAP) report, where we discuss the various metrics being followed in this trial and the tremendous performance of the approximately 70 sites participating in the CLEAR III intraventricular hemorrhage trial.

Another notable milestone: the results of the closely-related MISTIE II trial in intracerebral hematoma will be presented by Dr. Daniel Hanley at the International Stroke Conference in New Orleans on February 1st. Check the MISTIE study blog for details.

FEB
28

MISTIE Investigators Recognized for Saving a Man's Life

Issam Awad, MD, and Joseph Pagone Joseph Pagone, 53, collapsed in his shower with a loud thud. The impact startled his wife, Jan, who ran to the bathroom to find him struggling to get up. His dominant right side was useless.

Continue reading

MISTIE-3 Site Locations